Job Watch

Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Human Tissue Core (U01- Clinical Trial Not Allowed)

Funding Opportunity RFA-HL-19-021 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.

Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Data Coordinating Center (U24- Clinical Trial Not Allowed)

Funding Opportunity RFA-HL-19-022 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U24) applications to serve as the Data Coordinating Center (DCC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The DCC will perform data collection, integration, and analysis; develop and maintain the LungMAP database and website; and coordinate research activities of the Human Tissue Core (HTC) and the Research Centers (RCs). Applicants are not required to have been funded in Phase 1 (RFA-HL-14-009) in order to submit applications for Phase 2.

Sr. Data Scientist - Celgene Corporation - Seattle, WA

Indeed.com - Bioinformatics - Fri, 2018-07-27 06:49
Work with computational biologists, computational scientists, biostatisticians and study scientists to resolve any data issues found during analysis....
From Celgene - Fri, 27 Jul 2018 10:49:56 GMT - View all Seattle, WA jobs
Categories: Job Watch

EMBL: Bioinformatics/Data Curation Internship: Identifiers.org

New Scientist - Bioinformatics - Fri, 2018-07-27 05:39
Competitive Salary: EMBL: Bioinformatics/Data Curation Internship: Identifiers.orgLocation:EMBL-EBI Hinxton near Cambridge, UK Staff Category:TraineeContract Duration:6 months Hinxton, Cambridgeshire, England
Categories: Job Watch

Pediatric Critical Care and Trauma Scientist Development Program (K12 Clinical Trial Optional)

Funding Opportunity RFA-HD-19-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support a national program of mentored advanced career development and training in research for junior faculty in pediatric critical care medicine and pediatric trauma surgery. Such a program is necessary to fuel the pipeline of well trained young investigators and advance research in these two clinically demanding fields.

Confidentiality in AHRQ-Supported Research

Notice NOT-HS-18-012 from the NIH Guide for Grants and Contracts

Expanding Extramural Research Opportunities at the NIH Clinical Center (U01 Clinical Trial Optional)

Funding Opportunity PAR-18-879 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support extramural investigator-initiated clinical research in collaboration and partnership with intramural investigators at the NIH Clinical Center in Bethesda, MD. This new FOA will leverage the resources (inpatient and outpatient) and assets of the NIH Clinical Center (e.g., scientific, clinical trial and expertise, nursing, beds, critical care services, ambulatory care services, laboratories, imaging, biostatistics, protocol development, regulatory guidance, clinical trials management and safety oversight) in accelerating the discovery and translation from lab to clinic of therapies for allergy, asthma, autoimmune disease and transplantation. Extramural scientists proposing research within NIAIDs priorities has the opportunity to utilize this unique resources of the Clinical Center (for a description of resources, see https://clinicalcenter.nih.gov/translational-research-resources/resources.html). This FOA will specifically support hypothesis-driven mechanistic studies alone or within clinical projects employing small Phase 0, 1, and/or 2a clinical trial designs.

Late Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)

Funding Opportunity PAR-18-878 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R01 grant applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.

Early Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)

Funding Opportunity PAR-18-877 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose to develop and implement early stage (Phase I or II) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance trial design and methods.

NIAID T32 and T35 Training Grants Maximum Number of Trainee Slots

Notice NOT-AI-18-044 from the NIH Guide for Grants and Contracts

Genetics Research Scientist - Wisconsin Cooperative Fishery Research Unit - UW Stevens Point - Stevens Point, WI

Indeed.com - Bioinformatics - Wed, 2018-07-25 15:32
Individuals with disabilities who need a reasonable accommodation during the application or interview process should contact Human Resources and Affirmative... $50,000 a year
From University of Wisconsin System - Wed, 25 Jul 2018 19:32:10 GMT - View all Stevens Point, WI jobs
Categories: Job Watch

Human Islet Research Enhancement Center for the Human Islet Research Network (U24 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-18-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement will provide support for a Human Islet Research Enhancement Centerthat will supply the infrastructure needed to support research coordination, collaboration and dissemination of advances made by the NIDDK funded Human Islet Research Network (HIRN).

Center for ELSI Resources and Analysis (U24 Clinical Trial Not Allowed)

Funding Opportunity RFA-HG-18-008 from the NIH Guide for Grants and Contracts. The NHGRI Ethical, Legal and Social Implications (ELSI) Research Program solicits applications to develop and implement a Center for ELSI Resources and Analysis (CERA). The proposed Center will: 1) provide ELSI researchers with an established platform to share their research tools and products related to genomics; 2) serve as a resource that curates and synthesizes ELSI research on key topics in the field, highlights new findings and provides access to these works; and 3) convene ELSI researchers for both small and large scale transdisciplinary projects and meetings to develop a more synergistic and integrated ELSI research community.

Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)

Funding Opportunity RFA-AG-19-021 from the NIH Guide for Grants and Contracts. The goal of the GEMSSTAR program is to provide support for early-career physician-scientists trained in medical or surgical specialties or early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. To achieve this goal, the GEMSSTAR FOA provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects. The GEMSSTAR program also encourages candidates to seek out a supportive research environment to achieve the program's goal of fostering the development of early-career physician- and dentist-scientists in aging- or geriatric-focused research, particularly as it applies to their clinical specialty/discipline. In selecting GEMSSTAR awardees, NIA will consider the extent to which a candidate's environment is supportive of aging- or geriatric-focused research.

Innovative Technologies to Non-Invasively Monitor Genome Edited Cells In Vivo (UH2/UH3 Clinical Trial Not Allowed)

Funding Opportunity RFA-RM-18-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development of innovative technologies to non-invasively label and monitor genome edited cells in vivo. The ultimate goal for these technologies is to inform on safety and efficacy of in vivo genome editing over time.

Pages

Subscribe to Anil Jegga aggregator - Job Watch